Enanta Pharmaceuticals (ENTA) AI Stock Analysis

• Market Cap: $368.55M
• Dividend Yield: N/A
• Average Volume (3M): 190.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.62
• Revenue Growth: -3.42%
• EPS Growth: 30.03%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.42
• Shares Outstanding: 29,019,344
• 10 Day Avg. Volume: 189,752
• 30 Day Avg. Volume: 190,222
• PEG Ratio: 0.10
• Price to Book (P/B): 3.95
• Price to Sales (P/S): 3.91
• P/FCF Ratio: -7.94
• Enterprise Value/Market Cap: 1.23
• Enterprise Value/Revenue: 6.76
• Enterprise Value/Gross Profit: 6.76
• Enterprise Value/Ebitda: -7.67
• 1Y Price Target: $19.50
• Price Target Upside: 46.95% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -2.76
• Revenue Forecast (FY): $65.78M

• Rating: 52 Neutral
• Price Target: $14.50 ▲(9.27% Upside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is primarily constrained by weak financial performance—large ongoing losses and continued cash burn—despite improved revenue momentum and a healthier leverage profile. Technicals are moderately supportive with price holding above key moving averages and neutral momentum. Valuation is limited by negative earnings, while the corporate event is modestly positive for governance but includes potential dilution from additional incentive-plan shares.

Positive Factors

Partnership-driven business model

Enanta’s model generates upfront payments, research funding, milestone payments and royalties from partners, providing multiple non-dilutive funding channels. This partnership-heavy approach de-risks R&D, smooths funding needs relative to pure internal-funding models, and supports sustained program advancement over months.

Revenue rebound and strong gross margin

A sharp revenue recovery combined with ~72% gross margin indicates favorable economics in product/partner revenue mix and effective cost of goods control. High gross margin provides room to invest in R&D while moving toward operating leverage if revenue growth continues, making margins more sustainable across quarters.

Improved leverage and balance-sheet flexibility

A materially improved debt-to-equity ratio and positive equity provide greater financial flexibility to fund clinical programs or absorb timing lags in partner payments. Moderate leverage lowers near-term refinancing risk and supports strategic options such as selective M&A, licensing, or extending program timelines without immediate capital raises.

Negative Factors

Persistent negative operating cash flow

Sustained operating and free cash flow outflows increase funding risk and constrain the company’s ability to self-fund clinical development. Over a multi-month horizon, continued cash burn can force dilutive financings or accelerated partner dependency, limiting strategic flexibility and possibly delaying program timelines.

Large operating losses and negative margins

Deep operating losses and materially negative net margins indicate the current cost structure far exceeds revenue run-rate. If losses persist, they will erode equity and deter reinvestment; achieving break-even requires sustained revenue growth or material cost reduction, a multi-quarter challenge given clinical-stage expense profiles.

Revenue dependent on partner milestones and royalties

Heavy reliance on milestone-triggered payments and royalties makes revenue lumpy and visibility poor. Structural unpredictability complicates planning for R&D spend and cash runway; delays or cessation of partner payments would materially reduce near-term cash inflows and could necessitate financing or program cuts.

Enanta Pharmaceuticals Business Overview & Revenue Model

Company Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

Enanta primarily makes money through (1) collaboration and licensing revenue and (2) potential future product revenue if it commercializes any of its wholly owned drug candidates. Collaboration/licensing revenue is generated by granting partners rights to use or develop Enanta-discovered compounds and intellectual property in exchange for upfront payments, research funding and cost reimbursement (where applicable), development and regulatory milestone payments triggered by progress in clinical trials/approvals, and royalties on net sales of partnered products if they reach the market. A key historical source of earnings has been royalties and other payments tied to a partnered hepatitis C virus (HCV) protease inhibitor discovered by Enanta and commercialized by AbbVie as part of its HCV regimen, which produced ongoing royalty income while the product was sold. In addition, Enanta can earn periodic payments under other partnering arrangements (including option, license, and research collaborations) when contractual milestones are achieved. Enanta also uses its cash to fund internal R&D; because it is largely a development-stage company, its results are heavily influenced by the timing and magnitude of partner milestone events and any remaining royalty streams, as well as its ability to secure new partnerships for its pipeline.

Enanta Pharmaceuticals Financial Statement Overview

Summary

Revenue rebounded sharply and gross margin is healthy (~72%), and leverage has improved to a more moderate level. However, results remain dominated by large operating losses and materially negative margins, with continued negative operating cash flow/free cash flow, keeping overall financial quality weak despite balance-sheet progress.

Income Statement

TTM (Trailing-Twelve-Months) revenue rebounded sharply (strong positive growth), and gross margin remains healthy (~72%). However, profitability is still very weak: the company is operating at large losses (EBIT and EBITDA deeply negative) and net margin is materially negative, indicating the current cost structure is not supported by the revenue base. Compared with recent annual periods, losses have narrowed somewhat, but the business is still far from break-even.

Balance Sheet

The balance sheet improved meaningfully versus the most recent annual snapshot: leverage is now moderate (debt-to-equity ~0.45 in TTM (Trailing-Twelve-Months) vs. very high in the latest annual period). Equity remains positive and assets are sizable, providing financial flexibility. The key weakness is continued value erosion from losses, reflected in strongly negative returns on equity, which can pressure the balance sheet if losses persist.

Cash Flow

Cash generation remains negative: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are both outflows, and free cash flow deteriorated versus the prior period (negative growth). A positive point is that free cash flow is less negative than net income (cash burn smaller than accounting loss), suggesting meaningful non-cash charges and/or working-capital support. Still, ongoing cash burn elevates funding risk if sustained.

Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	66.98M	65.32M	67.64M	79.20M	86.16M	97.07M
Gross Profit	66.98M	60.74M	67.64M	79.20M	86.16M	97.07M
EBITDA	-59.03M	-70.78M	-104.51M	-123.48M	-119.22M	-104.25M
Net Income	-71.54M	-81.89M	-116.05M	-133.82M	-121.75M	-79.00M
Balance Sheet
Total Assets	329.50M	280.73M	376.65M	462.27M	380.59M	440.86M
Cash, Cash Equivalents and Short-Term Investments	185.85M	188.86M	248.19M	369.91M	249.23M	244.00M
Total Debt	193.18M	201.06M	226.06M	222.44M	26.69M	6.83M
Total Liabilities	202.91M	216.01M	247.84M	245.54M	59.26M	41.43M
Stockholders Equity	126.59M	64.72M	128.81M	216.74M	321.33M	399.43M
Cash Flow
Free Cash Flow	-18.46M	-32.17M	-96.71M	-112.21M	-86.91M	-70.75M
Operating Cash Flow	-14.17M	-19.27M	-78.76M	-103.15M	-84.78M	-70.00M
Investing Cash Flow	-75.85M	40.35M	58.23M	-53.58M	54.90M	36.99M
Financing Cash Flow	42.50M	-26.62M	-27.63M	198.13M	20.03M	3.08M

Enanta Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 13.27
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENTA, the sentiment is Neutral. The current price of 13.27 is below the 20-day moving average (MA) of 13.96, below the 50-day MA of 13.57, and above the 200-day MA of 10.85, indicating a neutral trend. The MACD of -0.15 indicates Positive momentum. The RSI at 45.11 is Neutral, neither overbought nor oversold. The STOCH value of 13.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ENTA.

Enanta Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALLO	56 Neutral	$524.12M	-1.58	-57.07%	―	-100.00%	37.10%
TECX	54 Neutral	$603.67M	-5.15	-26.87%	―	―	60.40%
ENTA	52 Neutral	$368.55M	-7.06	-78.59%	―	-3.42%	30.03%
JBIO	52 Neutral	$679.58M	-3.80	-50.23%	14.68%	―	89.16%
NMRA	52 Neutral	$441.12M	-1.30	-113.81%	―	―	20.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ABEO	47 Neutral	$259.57M	3.92	53.18%	―	―	―

Enanta Pharmaceuticals Corporate Events

Enanta Shareholders Approve Board Elections and Equity Plan

At its annual meeting on March 11, 2026, Enanta Pharmaceuticals’ shareholders re-elected Bruce L.A. Carter, Ph.D., and Jay R. Luly, Ph.D., as Class I directors to serve until the 2029 annual meeting, reinforcing continuity in the company’s board leadership. Stockholders also approved an amendment to the 2019 Equity Incentive Plan, adding 1.6 million shares for potential issuance, which may support employee retention and align management incentives with long-term shareholder interests.

Shareholders further passed an advisory “say-on-pay” resolution endorsing the compensation of Enanta’s named executive officers, signaling broad investor support for current pay practices and governance. In addition, investors ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending September 30, 2026, maintaining continuity in financial oversight and reinforcing confidence in the company’s reporting framework.

The most recent analyst rating on (ENTA) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Enanta Pharmaceuticals stock, see the ENTA Stock Forecast page.